Blood cancers

ATAGI specifies which patients with haematological malignancy should have COVID-19 booster vax

People with blood cancers who are immunocompromised are now advised to have a third primary dose of COVID-19 vaccine with an mRNA vaccine. On 8 October the Australian Technical Advisory Group on Immunisation (ATAGI) recommended a booster third dose of vaccine as part of the primary course in individuals who are severely immunocompromised to address ...

Already a member?

Login to keep reading.

© 2021 the limbic